Statistics

Total Visits

Views
Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (52-Week) Improvement in Measures of Disease Activity in Patients with Psoriatic Arthritis: Results from 3 Phase 3, Randomized, Controlled Trials.7

Select a period of time:

Number of views in the range

Views
Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (52-Week) Improvement in Measures of Disease Activity in Patients with Psoriatic Arthritis: Results from 3 Phase 3, Randomized, Controlled Trials.3

Views

Views
April 20240
May 20241
June 20241
July 20241
August 20240
September 20240
October 20240
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States3
 

Top cities views

Views
Chicago1
Gallatin1